Page last updated: 2024-11-08

longifolene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

longifolene: from plant products; RN given refers to (1S-(1alpha,3abeta,4alpha,8abeta))-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1796220
CHEMBL ID519092
CHEBI ID49282
MeSH IDM0109019

Synonyms (45)

Synonym
einecs 207-491-2
1,4-methanoazulene, decahydro-4,8,8-trimethyl-9-methylene-, (1s,3ar,4s,8as)-
nsc 150808
1,4-methanoazulene, decahydro-9-methylene-4,8,8-trimethyl-, (1s-(1-alpha,3a-beta,4-alpha,8a-beta))-
(1s-(1alpha,3abeta,4alpha,8abeta))-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene
1,4-methanoazulene, decahydro-4,8,8-trimethyl-9-methylene-, (1s-(1alpha,3abeta,4alpha,8abeta))
1,4-methanoazulene, decahydro-4,8,8-trimethyl-9-methylene-
1,4-methanoazulene, decahydro-4,8,8-trimethyl-9-methylene-, (1s-(1alpha,3abeta,4alpha,8abeta))-
475-20-7
longifolene
junipen
d-longifolene
junipene
(+)-longifolene
kuromatsuen
longifolen
nsc-150808
kuromatsuene
[1s-(1alpha,3abeta,4alpha,8abeta)]-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene
(1s,3ar,4s,8as)-(+)-decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene
CHEBI:49282 ,
(+)-longifolen
(1s,3ar,4s,8as)-4,8,8-trimethyl-9-methylenedecahydro-1,4-methanoazulene
(1s,3ar,4s,8as)-4,8,8-trimethyl-9-methylidenedecahydro-1,4-methanoazulene
CHEMBL519092
longiforene
LMPR0103500017
3yxh7yy8wm ,
unii-3yxh7yy8wm
cas-475-20-7
NCGC00256076-01
dtxcid7027045
tox21_302307
dtxsid9047045 ,
(1s-(1.alpha.,3a.beta.,4.alpha.,8a.beta.))decahydro-4,8,8-trimethyl-9-methylene-1,4-methanoazulene
longifolene [inci]
.alpha.-longifolene
longifolene [mi]
S5614
AKOS030242126
HY-N6662
Q6673936
CCG-266608
CS-0083201
AS-56611
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
longifolene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID332912Antimicrobial activity Propionibacterium acnes ATCC 11827 after 2 days by broth dilution method1994Journal of natural products, Jan, Volume: 57, Issue:1
Naturally occurring antiacne agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (11.54)18.7374
1990's3 (11.54)18.2507
2000's6 (23.08)29.6817
2010's6 (23.08)24.3611
2020's8 (30.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (92.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]